MedDataX Logo

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT ID: NCT04147650

Last Updated: 2021-12-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

508 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-14

Study Completion Date

2020-10-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

NCT03597139

Dry Eye
COMPLETED PHASE2

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734

Keratoconjunctivitis Sicca
COMPLETED PHASE1

Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome

NCT03162094

Dry Eye Syndrome
UNKNOWN PHASE1/PHASE2

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920

Dry Eye Disease Kerato Conjunctivitis Sicca
COMPLETED PHASE2

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301

Keratoconjunctivitis Sicca
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 2/3, multi-center, randomized, double-masked, vehicle-controlled study to assess the efficacy and safety of three different concentrations of VOS when administered in both eyes (OU) twice a day (BID) over 12 weeks in subjects with mild to moderate DES. Subjects will undergo a 14- to 17-day run-in period in which VOS vehicle will be self-administered OU, BID. Subjects will be re-assessed to confirm they meet all of the inclusion criteria and none of the exclusion criteria. It is estimated that the study will enroll approximately 480 subjects across approximately 9 study centers. Eligible subjects will be randomized in a 1:1:1:1 ratio to one of the following study treatment groups after the 14- to 17-day run-in period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Syndrome Keratoconjunctivitis Sicca

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects will be randomized to one of the following treatment groups:

Investigational product (IP): one drop 0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks, one drop 0.10% VOS OU BID over 12 weeks, or one drop 0.20% VOS OU BID over 12 weeks.

Comparator: one drop VOS vehicle OU BID over 12 weeks.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Double masked

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.05% Voclosporin Ophthalmic Solution (VOS)

0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Group Type EXPERIMENTAL

0.05% Voclosporin Ophthalmic Solution (VOS)

Intervention Type DRUG

0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

0.10% VOS

0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Group Type EXPERIMENTAL

0.10% VOS

Intervention Type DRUG

0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

0.20% VOS

0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Group Type EXPERIMENTAL

0.20% VOS

Intervention Type DRUG

0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks

Group Type PLACEBO_COMPARATOR

Vehicle Ophthalmic Solution

Intervention Type DRUG

Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.05% Voclosporin Ophthalmic Solution (VOS)

0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention Type DRUG

0.10% VOS

0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention Type DRUG

0.20% VOS

0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention Type DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age.
* Have a documented history of Dry Eye prior to Visit 1.
* Willing and able to follow protocol procedures and instructions.

Exclusion Criteria

* Have undergone cataract or LASIK surgery within 1 year prior to Visit 1.
* Recent or current evidence of infection or inflammation in either eye.
* Current evidence of blepharitis, other meibomian gland dysfunction, conjunctivitis or history of herpes simplex or zoster keratitis in either eye.
* Have used any investigational drug or device within 30 days prior to Visit 1.
* Have used ophthalmic drugs (any topical eye medications) including prescription medication and over the counter (OTC) agents on the date of Visit 1.
* Have worn contact lenses 24 hours prior to Visit 1.
* Have used Xiidra® (lifitegrast) within 14 days prior to Visit 1.
* Have used Calcineurin Inhibitors (CNIs) such as Restasis® (cyclosporin ophthalmic emulsion) or CequaTM within 30 days prior to Visit 1.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aurinia Pharmaceuticals Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mary Palmen

Role: STUDY_DIRECTOR

Aurinia Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aurinia Investigative Center

Newport Beach, California, United States

Site Status

Aurinia Investigative Center

Colorado Springs, Colorado, United States

Site Status

Aurinia Investigative Center

Louisville, Kentucky, United States

Site Status

Aurinia Investigative Center

Lewiston, Maine, United States

Site Status

Aurinia Investigative Center

Andover, Massachusetts, United States

Site Status

Aurinia Investigative Center

Raynham, Massachusetts, United States

Site Status

Aurinia Investigative Center

Cranberry Township, Pennsylvania, United States

Site Status

Aurinia Investigative Center

Memphis, Tennessee, United States

Site Status

Aurinia Investigative Center

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol: Version 1.0

View Document

Document Type: Study Protocol: Version 2.0

View Document

Document Type: Study Protocol: Version 3.0

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AUR-VOS-2019-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
NCT05238597 COMPLETED PHASE2
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
NCT04735393 COMPLETED PHASE3
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
NCT06370039 COMPLETED PHASE2
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06493604 COMPLETED PHASE3
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT00404131 COMPLETED PHASE3
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
NCT05825352 COMPLETED NA
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02254265 COMPLETED PHASE2/PHASE3
Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
NCT02326090 COMPLETED PHASE2
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
NCT03088605 COMPLETED PHASE2
NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye
NCT00739349 COMPLETED PHASE2
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
NCT04556838 COMPLETED PHASE2
Study of SkQ1 as Treatment for Dry-eye Syndrome
NCT03764735 COMPLETED PHASE3
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
NCT00128245 COMPLETED PHASE2
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
NCT04206020 COMPLETED PHASE3
A Clinical Trial to Assess Subjects With Dry Eye Disease.
NCT04971031 COMPLETED PHASE2
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
NCT02365519 COMPLETED PHASE2
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
NCT03162783 COMPLETED PHASE2
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
NCT02040623 COMPLETED PHASE2
Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease
NCT02004067 COMPLETED PHASE4
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
NCT00679718 COMPLETED PHASE2
A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
NCT01478555 WITHDRAWN PHASE2
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
NCT03916042 COMPLETED PHASE2
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
NCT00680108 COMPLETED PHASE2
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT04498182 COMPLETED PHASE2
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT07179055 RECRUITING PHASE2